Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335273 | 1.00 | HIF1A (0.44) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL5981921 | 1.00 | HIF1A (0.44) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL5872532 | 1.00 | HIF1A (0.44) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL3619557 | 0.90 | HIF1A (0.43) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL3619552 | 0.90 | HIF1A (0.43) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL26787555 | 0.90 | TK1 (0.45) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL26787569 | 0.89 | HIF1A (0.41) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL26647531 | 0.89 | HIF1A (0.41) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL26787573 | 0.89 | HIF1A (0.42) | HIF1AADKTK1LMNASMN1; SMN2 | |
| SCHEMBL443066 | 0.85 | TK1 (0.46) | HIF1ATK1LMNASMN1; SMN2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | HIF1A 2249/4885ADK 7/4885TK1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.